当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2018年第21期
编号:13288032
IL—17与登革病毒感染致病关系的研究进展(5)
http://www.100md.com 2018年7月25日 《中国医药导报》 2018年第21期
     [27] Midgley CM,Bajwa-Joseph M,Vasanawathana S,et al. An in-depth analysis of original antigenic sin in dengue virus infection [J]. J Virol,2011,85(1):410-421.

    [28] Cruz Hernández SI,Puerta-Guardo HN,Flores Aguilar H,et al. Primary dengue virus infections induce differential cytokine production in Mexican patients [J]. Mem Inst Oswaldo Cruz,2016,111(3):161-167.

    [29] Murphy,B.R. and Whitehead,S.S. Immune response to dengue virus and prospects for a vaccine [J]. Annu Rev Immunol,2011,29(29):587-619.

    [30] Costa VV,Fagundes CT,Souza DG,et al. Inflammatory and innate immune responses in dengue infection:protection versus disease induction [J]. Am J Pathol,2013,182(6):1950-1961.

    [31] Furuta T,Murao LA,Lan NT,et al. Association of mast cell-derived VEGF and proteases in Dengue shock syndrome [J]. PLoS Negl Trop Dis,2012,6(2):e1505.

    [32] Jain A,Pandey N,Garg RK,et al. IL-17 Level in patients with Dengue virus infection & its association with severity of illness [J]. J Clin Immunol,2013,33(3):613-618.

    [33] Arias J,Valero N,Mosquera J,et al. Increased expression of cytokines,soluble cytokine receptors,soluble apoptosis ligand and apoptosis in dengue [J]. Virology,2014,452-453(2):42-51.

    (收稿日期:2018-04-10 本文編辑:苏 畅), http://www.100md.com(郑媛菲 刘凤辉 陈伟峰 巫慧文 张韵秦 )
上一页1 2 3 4 5